Cervical Cancer Stage IV Clinical Trial
Official title:
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Uterine Cervix and/or Vulva
Current therapies for Stage IV Cancer of the Cervix and/or Vulva provide very limited benefit
to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may
prove beneficial in the treatment of Stage IV Cancer of the Cervix and/or Vulva.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Stage IV Cancer of the Cervix and/or Vulva.
Stage IV Cancer of the Cervix and/or Vulva patients receive gradually escalating doses of
intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose
is reached. Treatment continues up to12 months in the absence of disease progression or
unacceptable toxicity.
OBJECTIVES:
- To determine the efficacy of Antineoplaston therapy in patients with Stage IV Cancer of
the Cervix and/or Vulva, as measured by an objective response to therapy (complete
response, partial response or stable disease).
- To determine the safety and tolerance of Antineoplaston therapy in patients with Stage
IV Cancer of the Cervix and/or Vulva.
- To determine objective response, tumor size is measured utilizing MRI scans, which are
performed every 8 weeks for the first two years, every 3 months for the third and fourth
years, every 6 months for the 5th and sixth years, and annually thereafter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03339765 -
Self-Advocacy Serious Game in Advanced Cancer
|
N/A |